RE:RE:RE:RE:RE:RE:How does Accelerated Approval work "Genentech’s Tecentriq won accelerated approval in 2016 for urothelial carcinoma but failed its overall survival endpoint in a Phase III trial the following year for patients with locally advanced or metastatic urothelial cancer who had been treated with platinum chemotherapy. It was withdrawn from the market in 2021 for this indication, with additional indications being pulled in 2022."
This demonstrates that Roche/Genentech's Tecentriq can significantly benefit from the addition of ONCY's drug platform pelareorep into their product portfolios given the synergistic benefit of pelareorep in an I/O combination with Tecentriq and pelareorep's putative 13 years of market exclusivity on approval for each indication approved.
https://www.biospace.com/article/cut-or-keep-running/